By Michael Dabaie

Minerva Neurosciences Inc. promoted Chief Financial Officer and Chief Business Officer Geoff Race to president as the company prepares to submit a pre-new drug application meeting request to the U.S. Food and Drug Administration.

The clinical-stage biopharmaceutical company focused on central nervous system disorders said it promoted Senior Vice President and Chief Accounting Officer Frederick Ahlholm to chief financial officer.

The company in late September reported results from a bioequivalence study comparing the roluperidone formulations used in late-stage Phase 2b and Phase 3 trials, and the planned commercial formulation.

The company plans to submit a pre-NDA meeting request to the FDA, with a potential NDA submission in the first half of 2022.

The data from September met all key pharmacokinetic objectives and the data demonstrated bioequivalence across the various formulations, the company said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

10-11-21 0907ET